ZyVersa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-8.84	-9.41	-98.3	-14.12	-8.08	-12.68
Depreciation & Amortization	0	0.01	0.01	0.01	0.01	0.01
Other Amortization	-	-	-	0.04	0.32	0.29
Asset Writedown & Restructuring Costs	-	-	93.33	-	-	-
Stock-Based Compensation	0.55	0.71	1.19	3.58	4.14	3.68
Other Operating Activities	0.21	0.21	-7.56	-0.05	-0.44	0.49
Change in Accounts Payable	1.25	0.75	2.41	4.54	-0.31	-0.6
Change in Other Net Operating Assets	1.28	0.18	0.19	1.12	-0.71	3.71
Operating Cash Flow	-5.56	-7.56	-8.72	-4.89	-5.08	-5.11
Long-Term Debt Issued	-	-	-	-	5.23	1.69
Net Debt Issued (Repaid)	-	-	-	-	5.23	1.69
Issuance of Common Stock	5.87	6.54	19.08	-	-	3.02
Repurchase of Common Stock	-	-	-0.01	-	-	-
Other Financing Activities	-0.74	-0.59	-2.42	-0.1	-	-0.14
Financing Cash Flow	5.13	5.95	5.96	1.87	5.23	4.56
Net Cash Flow	-0.42	-1.61	-2.76	-3.02	0.15	-0.55
Levered Free Cash Flow	-2.03	-4.09	-5.46	-1.65	-2.02	-
Unlevered Free Cash Flow	-1.79	-3.92	-5.46	-1.43	-1.83	-
Change in Net Working Capital	-2.79	-1.08	-2.35	-3.63	1.27	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q